Movers: Bank of America, Genentech, Schering-Plough, Merck

Stocks in the news on Monday Bank of America posts better-than-expected $0.72, vs. $1.28 a year ago, second quarter EPS as merger and restructuring costs offset 3.5% revenue rise, 26% rise in net interest income. Says provision for credit losses increased by $3.45 billion to $6.55 billion compared with a year earlier. Notes results excl. Countrywide Financial Corp., which was acquired on July 1. Merck and Schering-Plough shares fall after the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study investigating effects of intensive cholesterol lowering with combo of simvastatin and ezetimibe in patients with aortic stenosis showed no significant difference between treatment groups and placebo for primary endpoint (major cardiovascular events), nor for secondary endpoint of aortic valve disease events alone. Also, a total of... [read full story]